ESTRO 2024 - Abstract Book

S5435

Radiobiology - Tumour biology

ESTRO 2024

Figure 1: Barplot of the normalised enrichment scores for pathways jointly enriched for the high NAR group in the SCORT Grampian cohort and GSE87211 (adjusted p-value < 0.25).

Conclusion:

This data suggests reproducible biological differences regarding canonical signalling and immune activity between high NAR and low NAR tumours before nCRT. However, the differences observed do not appear distinct enough to predict the NAR score. Baseline transcriptomics may not be sufficient to determine treatment stratification before nCRT.

Keywords: Rectal adenocarcinoma, biomarker, transcriptomics

References:

(1) George TJ, Jr., Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. Curr Colorectal Cancer Rep. 2015;11(5):275-80.

(2) Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417-25.